bisdechlorogeodin: a fungus-derived nucleoside transport inhibitor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 168966 |
| CHEMBL ID | 512514 |
| CHEBI ID | 22899 |
| MeSH ID | M0107702 |
| Synonym |
|---|
| CHEBI:22899 , |
| bisdechlorogeodin |
| 3209-31-2 |
| methyl 4-hydroxy-6-methyl-4'-oxo-3h-spiro[1-benzofuran-2,1'-cyclohexa[2,5]diene]-2'-carboxylate |
| bis-dechlorogeodin |
| 4-hydroxy-6'-methoxy-6-methyl-3,4'-dioxo-spiro(benzofuran-2(3h),1'-(2,5)cyclohexadiene)-2'-carboxylic acid methyl ester |
| spiro(benzofuran-2(3h),1'-(2,5)cyclohexadiene)-2'-carboxylic acid, 4-hydroxy-6'-methoxy-6-methyl-3,4'-dioxo-, methyl ester |
| CHEMBL512514 |
| methyl 4-hydroxy-5'-methoxy-6-methyl-3,3'-dioxospiro[1-benzofuran-2,6'-cyclohexa-1,4-diene]-1'-carboxylate |
| c3368-a |
| antibiotic c3368-a |
| AKOS030213174 |
| Q27109574 |
| methyl 4-hydroxy-6'-methoxy-6-methyl-3,4'-dioxo-3h-spiro[1-benzofuran-2,1'-cyclohexa[2,5]diene]-2'-carboxylate |
| DTXSID00953966 |
| Role | Description |
|---|---|
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| oxaspiro compound | A spiro compound in which at least one of the cyclic components is an oxygen heterocyle. |
| 1-benzofurans | A member of the class of benzofurans consisting of a 1-benzofuran skeleton and its substituted derivatives thereof. |
| methyl ester | Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol. |
| cyclohexadiene | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID338306 | Antimicrobial activity against Escherichia coli at <200 ppm | 2002 | Journal of natural products, Jan, Volume: 65, Issue:1 | New chlorinated diphenyl ethers from an Aspergillus species. |
| AID338307 | Antimicrobial activity against Gaeumannomyces graminis var. tritici at <200 ppm | 2002 | Journal of natural products, Jan, Volume: 65, Issue:1 | New chlorinated diphenyl ethers from an Aspergillus species. |
| AID338309 | Antinematodal activity against Caenorhabditis elegans after 16 to 24 hrs | 2002 | Journal of natural products, Jan, Volume: 65, Issue:1 | New chlorinated diphenyl ethers from an Aspergillus species. |
| AID338308 | Antimicrobial activity against Rhizoctonia solani at <200 ppm | 2002 | Journal of natural products, Jan, Volume: 65, Issue:1 | New chlorinated diphenyl ethers from an Aspergillus species. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||